New combo therapy aims to rebuild immune defenses after harsh cancer treatment
NCT ID NCT05632809
Summary
This study is testing if an investigational drug called NKTR-255 can help restore the body's immune cells after patients with non-small cell lung cancer complete chemoradiation. The drug will be given alongside the standard immunotherapy durvalumab. Researchers want to see if this combination is safe and if it helps patients live longer without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact
Conditions
Explore the condition pages connected to this study.